LAUSR

Non‐Hodgkin's lymphoma‐tailored small compound inhibitors of BCR signaling, ibrutinib and idelalisib, where dramatic death rates were observed after priming with two restore agents. Further investigations, including pre‐clinical mouse trials, are currently in progress and will be reported at the meeting. Conclusions: In essence, we present here a novel “Restore & Target” strategy that builds on the re‐expression of a lost tumor cell phenotype in the first place followed by it specific exploration as druggable vulnerability in a subsequent step. Such a strategy would expand the arsenal of treatment options for cHL by a “chemo‐free” combination, and might not only be of interest for relapsed or refractory patients.